Chemical formula: C₁₉H₁₆F₂N₈O₂ Molecular mass: 426.388 g/mol
Vericiguat is a stimulator of soluble guanylate cyclase (sGC). Heart failure is associated with impaired synthesis of nitric oxide (NO) and decreased activity of its receptor, sGC. The pharmacodynamic effects of vericiguat are consistent with the mode of action of a sGC stimulator resulting in smooth muscle relaxation and vasodilation.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C01DX22 | C Cardiovascular system → C01 Cardiac therapy → C01D Vasodilators used in cardiac diseases → C01DX Other vasodilators used in cardiac diseases | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| VERQUVO Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Vericiguat is an active ingredient of these brands:
Austria (AT)Croatia (HR)Ecuador (EC)Estonia (EE)Finland (FI)France (FR)Ireland (IE)Israel (IL)Italy (IT)Japan (JP)Lithuania (LT)Poland (PL)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
